GGHC
RARE icon

Gilder Gagnon Howe & Co’s Ultragenyx Pharmaceutical RARE Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-121,941
Closed -$3.67M – 275
2025
Q3 		$3.67M Sell
121,941
-1,186
-1% -$35.6K 0.04% 168
2025
Q2 		$4.48M Buy
123,127
+106,239
+629% +$3.83M 0.05% 150
2025
Q1 		$612K Sell
16,888
-40
-0.2% -$1.66K 0.01% 204
2024
Q4 		$712K Sell
16,928
-2,661
-14% -$132K 0.01% 225
2024
Q3 		$1.09M Sell
19,589
-338
-2% -$17.2K 0.01% 206
2024
Q2 		$819K Buy
19,927
+2,504
+14% +$107K 0.01% 213
2024
Q1 		$813K Sell
17,423
-177
-1% -$8.35K 0.01% 219
2023
Q4 		$842K Buy
17,600
+8,008
+83% +$310K 0.01% 211
2023
Q3 		$342K Sell
9,592
-56
-0.6% -$2.22K 0.01% 238
2023
Q2 		$445K Buy
+9,648
New +$448K 0.01% 251
2022
Q3 		– Sell
-5,048
Closed -$301K – 254
2022
Q2 		$301K Sell
5,048
-1,703
-25% -$105K 0.01% 239
2022
Q1 		$490K Sell
6,751
-7,283
-52% -$507K ﹤0.01% 267
2021
Q4 		$1.18M Sell
14,034
-4,026
-22% -$328K 0.01% 289
2021
Q3 		$1.63M Sell
18,060
-284
-2% -$25.7K 0.01% 308
2021
Q2 		$1.75M Sell
18,344
-44
-0.2% -$4.58K 0.01% 308
2021
Q1 		$2.09M Sell
18,388
-4,896
-21% -$667K 0.01% 277
2020
Q4 		$3.22M Buy
+23,284
New +$2.76M 0.02% 232
2016
Q4 		– Sell
-6,840
Closed -$485K – 283
2016
Q3 		$485K Sell
6,840
-2
-0% -$128 0.01% 207
2016
Q2 		$335K Sell
6,842
-13
-0.2% -$841 0.01% 216
2016
Q1 		$434K Buy
+6,855
New +$449K 0.01% 182
2015
Q3 		– Sell
-4,235
Closed -$434K – 278
2015
Q2 		$434K Sell
4,235
-2,927
-41% -$227K 0.01% 233
2015
Q1 		$445K Sell
7,162
-162
-2% -$9K 0.01% 225
2014
Q4 		$321K Sell
7,324
-243
-3% -$11.1K ﹤0.01% 234
2014
Q3 		$428K Sell
7,567
-22
-0.3% -$1.11K 0.01% 235
2014
Q2 		$341K Sell
7,589
-12,702
-63% -$523K ﹤0.01% 252
2014
Q1 		$992K Buy
+20,291
New +$1.04M 0.01% 212

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Gilder Gagnon Howe & Co's RARE Position: Q4 2025 in Review

Gilder Gagnon Howe & Co sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2025, closing a stake of 121,941 shares — an estimated $3.67M sold.

Gilder Gagnon Howe & Co first reported a position in RARE in Q1 2014 and held it in 26 quarters. The position peaked at $4.48M in Q2 2025. 288 funds tracked by Wall St. Rank hold RARE as of Q4 2025.

  • Gilder Gagnon Howe & Co reported no remaining Ultragenyx Pharmaceutical position as of Q4 2025 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 121,941 Ultragenyx Pharmaceutical shares in Q4 2025, an estimated $3.67M.
  • Gilder Gagnon Howe & Co first reported a position in Ultragenyx Pharmaceutical in Q1 2014 and held it in 26 quarters.
  • Gilder Gagnon Howe & Co's Ultragenyx Pharmaceutical position peaked at $4.48M in Q2 2025.
  • 288 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2025.

Based on Gilder Gagnon Howe & Co's 13F filing for Q4 2025, filed 17 Feb 2026.